Tandem Diabetes Care (TNDM) Non Operating Interest Expenses (2023 - 2026)

Tandem Diabetes Care (TNDM) has reported Non Operating Interest Expenses for 4 consecutive years, with $2.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Non Operating Interest Expenses rose 28.61% year-over-year to $2.4 million; the trailing twelve-month figure through Jun 2026 stood at $8.8 million (up 17.38% YoY), and the FY2025 full-year result was $7.9 million, up 6.64% from the prior year.
• Non Operating Interest Expenses improved to $2.4 million in Q2 2026 per TNDM's latest filing, from $2.2 million in the prior quarter.
• Across five years, Non Operating Interest Expenses topped out at $4.8 million in Q3 2023 and bottomed at $1.6 million in Q2 2023.
• Historically, Non Operating Interest Expenses has averaged $2.2 million across 4 years, with a median of $1.9 million in 2024.
• The sharpest annual moves came in 2024 and 2026: Non Operating Interest Expenses plunged 61.47% in 2024, then gained 28.61% in 2026.
• Over 4 years, Non Operating Interest Expenses stood at $1.8 million in 2023, then gained by 3.16% to $1.9 million in 2024, then advanced by 11.56% to $2.1 million in 2025, then gained by 18.07% to $2.4 million in 2026.
• According to Business Quant data, Non Operating Interest Expenses over the past three periods registered $2.4 million, $2.2 million, and $2.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.